Mar 2018



Aug 2019



Mar 2017

Oct 2012

Phase II trial of cannabidiol for Parkinson's psychosis - King's College London 

£1.2 million over 42 months (currently active)

​A 6-week pilot and 12-week double, blind placebo-controlled trial to provide preliminary evidence for the safety and efficacy of cannabidiol (CBD) capsules for the treatment of Parkinson's-related psychosis.

Novel mitochondrial rescue compounds - University of Sheffield 

£98,000 over 12 months (currently active)

Screening and in vitro testing programme to identify compounds that rescue mitochondrial function with reduced off-target effects.

Novel mPTP inhibitors - NRG Therapeutics

£1 million over 12 months (currently active)

A preclinical programme to discover and develop a potential drug that could safeguard the dopaminergic cells damaged by Parkinson's and slow down the progression of the condition.

Novel gene transcription modulators - Eurofins Selcia Drug Discovery

£2.5 million over 24 months (currently active)

A drug discovery and development programme to create molecules that increase the activity of genes  to increase dopamine synthesis and boost the production of neuroprotective proteins.

Serotonin 5-HT1A receptor agonist, NLX-112 - Neurolixis

£780,000 over 15 months

This project supported the final pre-clinical studies for NLX-112, a novel serotonin 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia.

Novel Nrf2-KEAP1 inhibitors - Keapstone Therapeutics Limited

£2.3 million over 28 months

A drug discovery and development programme that developed and optimised novel inhibitors of the interaction between NFE2-related factor 2 (Nrf2) and Kelch-like ECH associated protein 1 (KEAP1).

Glial cell line-derived neurotrophic factor - Medgenesis Therapeutics Inc.

£2.5 million over 62 months

A placebo-controlled, randomised, double-blind trial that assessed the safety and efficacy of intermittent bilateral intraputamenal glial cell line-derived neurotrophic factor (GDNF) infusions administered via convection enhanced delivery (CED) in subjects with Parkinson’s disease.